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The neuroprotective potency of estradiol (E2) in
different animal models of neurodegeneration, cogni-
tive decline, and affective disorders has been extensively
characterized in the last decades (Garcia-Segura &
Balthazart 2009). However, the application of E2 as a
neuroprotectant in humans presents numerous limi-
tations, mainly due to the endocrine actions of the
molecule on peripheral tissues, including estrogen-
dependent tumors. The possibility of using selective
estrogen receptor modulators (SERMs) to exert E2-like
neuroprotective actions in the brain has emerged as an
alternative to E2 (DonCarlos et al. 2009). According to
chemical family, SERMs are classified as triphenyleth-
ylene, benzothiophene, or benzopyran compounds.
Triphenylethylene SERMs, such as tamoxifen and its
derivatives, are also known as first-generation SERMs.
Benzothiophene SERMs include second-generation
SERMs, such as raloxifene, and third-generation
SERMs. Fourth-generation SERMs are benzopyran
compounds (Dowers et al. 2006). SERMs bind to
estrogen receptors (ERs) and induce specific changes
in their three-dimensional conformation (Brzozowski
et al. 1997, Paige et al. 1999) allowing a tissue-selective
recruitment of transcriptional cofactors (Norris et al.
1999, Klinge 2000, McKenna & O’Malley 2002, Belandia
& Parker 2003). Therefore, SERMs may act as ERJournal of Molecular Endocrinology (2011) 46, R1–R9
0952–5041/11/046–R1 q 2011 Society for Endocrinology Printed in Great Britainagonists in the brain and as antagonists in others
tissues, such as breast tumors. Here, we will briefly
review new advances on the research associated with the
potential use of SERMs as neuroprotective agents.Neuroprotective actions of SERMs
The neuroprotective actions of tamoxifen and ralox-
ifene, two SERMs that are currently used in clinical
practice for the treatment of breast cancer and
osteoporosis, have been assessed in different experi-
mental models of neural dysfunction. These include
animal models of traumatic injury of the central
nervous system and peripheral nerves, stroke, multiple
sclerosis, Parkinson’s disease, Alzheimer’s disease,
cognitive decline, and mood disorders (Fig. 1). This
section is a succinct description of the main findings of
these experimental studies, including the limited
available information from human studies.Brain, spinal cord, and peripheral nerve injury
Tamoxifen is a protective factor for spinal cord injury.
Treatment with tamoxifen, 30 min after spinal cord
injury, results in a decrease in blood spinal cord barrier
permeability, reduced edema, reduced microglial
activation, decreased myelin and neuronal loss, andDOI: 10.1677/JME-10-0122
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Figure 1 Summary of the neuroprotective effects of SERMs
reported in animal models of neurodegenerative, cognitive, and
affective disorders.
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In addition, tamoxifen and raloxifene reduce reactive
gliosis after a traumatic brain injury (Barreto et al.
2009), and raloxifene has been shown to improve
functional recovery after bilateral cortical contusion
injury (Kokiko et al. 2006). Tamoxifen may also be
useful to reduce irradiation-induced brain damage
after whole brain irradiation therapy (Liu et al. 2010).
SERMs may also have potential application for the
regeneration of peripheral nerves, since the raloxifene
analog LY117018 increases the number of regenerating
nerve fibers after sciatic nerve crush injury in mice
(McMurray et al. 2003).Stroke
Tamoxifen reduces tissue infarction and behavioral
deficits in animal experimental models of stroke
(Kimelberg et al. 2003, Mehta et al. 2003, Feng et al.
2004, Kimelberg 2008) and attenuates neuronal
excitability impairment caused by ischemic conditions
in rat hippocampal slices incubated in oxygen-depleted
and glucose-deprived medium (Zhang et al. 2009). The
raloxifene analog LY353381.HCl is also neuroprotec-
tive in experimental stroke (Rossberg et al. 2000).
However, it has been reported that raloxifene may
increase the risk of stroke in a subpopulation of
women at high stroke risk (Barrett-Connor et al. 2009,
Mosca et al. 2009).Multiple sclerosis
SERMs may reduce inflammation in the central nervous
system (see below) and may therefore represent
interesting therapeutic candidates for multipleJournal of Molecular Endocrinology (2011) 46, R1–R9sclerosis. Indeed, tamoxifen reduces in mice the degree
of demyelination caused by experimental autoimmune
encephalomyelitis (Bebo et al. 2009).Parkinson’s disease
Tamoxifen prevents the loss of dopaminergic function
in the nigrostriatal system caused by methamphetamine
in mice (Mickley & Dluzen 2004, Bourque et al. 2007).
However, the neuroprotective properties of estrogen
against Parkinson’s disease occurrence may be dis-
rupted by tamoxifen therapy in breast cancer patients
(Latourelle et al. 2010). Raloxifene has agonistic
estrogenic activity on dopamine receptors (Landry
et al. 2002) and protects dopaminergic neurons in
experimental animal models of Parkinson’s disease
(Grandbois et al. 2000, Callier et al. 2001, Morissette
et al. 2008).Alzheimer’s disease
Tamoxifen protects neurons against b-amyloid toxicity
(O’Neill et al. 2004). Some human studies also suggest
that tamoxifen may decrease the risk of Alzheimer’s
disease (Breuer & Anderson 2000). Raloxifene has
been shown to protect PC12 neural cells against
b-amyloid-induced neurotoxicity (Du et al. 2004).Cognitive decline
In spite of the neuroprotective actions of tamoxifen in
different forms of neural injury, it is unclear whether
this molecule may have some benefits for cognition in
humans. Indeed, several studies suggest an increased
risk of cognitive impairment in women receiving
tamoxifen for the treatment of breast cancer, including
worse performance in visual memory, word fluency,
immediate verbal memory, visuospatial ability, and
processing speed tasks (Paganini-Hill & Clark 2000,
Shilling et al. 2003, Palmer et al. 2008, Phillips et al. 2010,
Schilder et al. 2010). However, other studies have not
detected a significant effect of tamoxifen on cognition
(Debess et al. 2010).
In contrast to the potential negative effects of
tamoxifen on cognition, the results of the multiple
outcomes of raloxifene evaluation randomized trial
suggest that raloxifene prevents cognitive decline in
postmenopausal women (Yaffe et al. 2005). The results
of a recent randomized, double-blind, placebo-con-
trolled trial also suggest that raloxifene improves verbal
memory in late postmenopausal women ( Jacobsen et al.
2010). In addition, raloxifene treatment enhances
brain activation during performance on a face-encod-
ing paradigm and during recognition of familiar items
in healthy elderly men (Goekoop et al. 2005, 2006),www.endocrinology-journals.org
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cognition in men. In agreement with this possibility,
we have recently observed that both tamoxifen
and raloxifene improve hippocampus-dependent
memory in androgen-deprived male rats (N Lagunas,
I Calmarza-Font, D Grassi & LM Garcia-Segura,
unpublished observations).Affective disorders
Some studies have suggested a potential therapeutic effect
of tamoxifen for the treatment of affective disorders.
Tamoxifen reduces amphetamine-induced manic-like
behavioral alterations in rats (Einat et al. 2007) and
reduces acute manic episodes in women with bipolar
affective disorder (Kulkarni et al. 2006, Zarate et al. 2007).
Raloxifene reduces anxiety behavior, assessed in the
elevated plus maze test, on ovariectomized rats (Walf &
Frye 2010) and decreases anxiety (Strickler et al. 2000,
Florio et al. 2001) and depression (Carranza-Lira et al.
2004, Grigoriadis et al. 2005, Sugiyama et al. 2007)
in postmenopausal women. Recent clinical studies
also suggest the potential application of raloxifene
hydrochloride (120 mg/day oral) for the treatment of
postmenopausal women with schizophrenia (Kulkarni
et al. 2010).SERMs and neuroprotection: a summary of
the findings
We can conclude that the studies conducted so far to
evaluate the neuroprotective activity of tamoxifen and
raloxifene indicate that these SERMs decrease
neuronal damage caused by different forms of neural
injury in animal models of neurodegenerative diseases.
However, animal models of neurodegeneration do not
fully reflect the situation in human pathology. There-
fore, whether these findings in animals could be
translated to human health is still an open question.
Nevertheless, the limited information from human
studies suggests that SERMs may have a positive impact
on mood and cognition, at least under certain
circumstances. These findings justify further research
on the possible application of SERMs for the treatment
of brain disorders.Molecular mechanisms involved in the
neuroprotective actions of SERMs
SERMs signal on neural cells by multiple mechanisms
that may contribute to neuroprotection (Dhandapani
& Brann 2002). Some neuroprotective actions of
SERMs may be due to mechanisms independent
of their activity as ER modulators. For instance,www.endocrinology-journals.orgthe efficacy of tamoxifen in the treatment of acute
mania has been ascribed to its action as a protein kinase
C inhibitor (Einat et al. 2007, Zarate et al. 2007). Other
neuroprotective mechanisms of SERMs are mediated by
classical ERs, since they are inhibited by ER antagonists,
such as ICI 182 780 (Zhang et al. 2009). The
neuroprotective signaling of SERMs may involve the
activation of kinases, such as mitogen-activated protein
kinase (MAPK), phosphatidylinositol 3-kinase (PI3K),
and Akt (Du et al. 2004, Lee et al. 2009a,b), and the
phosphorylation of CREB (Sharma et al. 2007) or the
inhibition of nuclear factor (NF)-kB-induced transcrip-
tion (Cerciat et al. 2010). Through these mechanisms,
SERMs control synaptic transmission and the
expression of molecules involved in the regulation of
cell death, oxidative stress, and inflammation.
We will consider here five important interrelated
actions of SERMs in the nervous system that may be
highly relevant for their neuroprotective activity: i) the
modulation of synaptic transmission; ii) the control of
oxidative stress; iii) the control of excitotoxic damage;
iv) the control of the apoptotic program; and v) the
control of inflammation.Modulation of synaptic transmission
Some SERMs promote axonal growth (Nilsen et al.
1998, O’Neill et al. 2004) and the expression of synaptic
markers (Sharma et al. 2007), suggesting possible
actions on synaptic plasticity and synaptic regeneration.
These actions, which are still not sufficiently investi-
gated, may contribute to the maintenance of functional
neuronal circuits and to the repair of damaged
connectivity. Actions of SERMs on mood and cognition
may also be related with their pre- and post-synaptic
modulation of cholinergic, serotonergic, and dopamin-
ergic neurotransmission (Wu et al. 1999, Cyr et al. 2000,
Smith et al. 2004, Sa´nchez et al. 2010). Raloxifene may
also regulate opiate and GABAergic neurotransmission
by the modulation of the levels of b-endorphin and
neuroactive steroids respectively. Chronic raloxifene
administration to postmenopausal women increases
plasma levels of b-endorphin and tetrahydroprogester-
one (allopregnanolone), an anxiolytic metabolite of
progesterone that modulates GABAA receptors (Florio
et al. 2001, Neele et al. 2002, Bernardi et al. 2003,
Genazzani et al. 2003). Changes in the levels of
b-endorphin and tetrahydroprogesterone in plasma
probably parallel similar changes in the nervous system,
since in ovariectomized rats, the raloxifene analog
LY117018 has been shown to increase b-endorphin and
tetrahydroprogesterone levels not only in serum but
also in the brain (Genazzani et al. 1999, 2000, Bernardi
et al. 2003). These findings suggest that raloxifene may
regulate synaptic function by the modulation of local
levels of neuroactive substances within the brain.Journal of Molecular Endocrinology (2011) 46, R1–R9
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The well-documented antioxidant effects of tamoxifen,
hydroxytamoxifen, and raloxifene in the nervous tissue
(Moreira et al. 2004, 2005, Biewenga et al. 2005,
Konyalioglu et al. 2007, Armagan et al. 2009) may be
relevant for its neuroprotective actions on Parkinson’s
disease (Lee et al. 2009a,b), cerebral ischemia (Zhang
et al. 2007, Wakade et al. 2008), and other neuro-
degenerative conditions.Lasofoxifene + KA Bazedoxifene + KA
60 µmControl of excitotoxic damage
An important neuroprotective action of SERMs is the
prevention of excitotoxicity, since this is a common
cause of neuronal death in different neurodegenerative
disorders. Several SERMs have shown to reduce
neuronal loss in the hippocampus after the adminis-
tration of the excitotoxin kainic acid (Ciriza et al. 2004).
Figure 2 shows the effect of tamoxifen, raloxifene,
lasofoxifene, and bazedoxifene on hilar neurons
of ovariectomized rats injected with kainic acid.
Tamoxifen, raloxifene, and bazedoxifene prevent the
excitotoxic effect of kainic acid in this model.Figure 2 SERMs prevent excitotoxic neuronal death in vivo after
kainic acid administration. High magnification of the hilus of the
dentate gyrus of ovariectomized rats stained with toluidine blue
after the i.p. injection of vehicle (Control); kainic acid (KA;
7 mg/kg); tamoxifen (1 mg/kg) and kainic acid; raloxifene
(1 mg/kg) and kainic acid; lasofoxifene (1 mg/kg) and kainic
acid; bazedoxifene (2 mg/kg) and kainic acid. Kainic acid results
in the loss of hilar neurons (large cells). Small cell nuclei
correspond to glial cells. Some SERMs, such as tamoxifen,
raloxifene, and bazedoxifene, prevent the excitotoxic effect of
kainic acid. Adapted, with permission, from Ciriza I, Carrero P,
Azcoitia I, Lundeen SG & Garcia-Segura LM 2004 Selective
estrogen receptor modulators protect hippocampal neurons
from kainic acid excitotoxicity: differences with the effect of
estradiol. Journal of Neurobiology 61 209–221. q 2004 Wiley
Periodicals, Inc.Control of the apoptotic program
The neuroprotective actions of SERMs on excitotoxicity
and against other neural insults may be mediated by the
regulation of molecules involved in the control of
apoptosis. For instance, raloxifene increases the
expression of Bcl-2 in the cerebral cortex of ovari-
ectomized rats treated with kainic acid (Armagan et al.
2009), and chronic administration of tamoxifen to
ovariectomized rats increases the expression of Bcl-2
and decreases the expression of Bax in the hippo-
campus (Sharma & Mehra 2008). Furthermore, tamox-
ifen and raloxifene up-regulate the expression of the
antiapoptotic gene seladin-1 (selective Alzheimer’s
disease indicator-1) in human neuroblasts (Benvenuti
et al. 2005). SERMs may also prevent neuronal apoptosis
by the activation of telomerase activity via Akt and
the phosphorylation of telomerase catalytic subunit
(TERT; Du et al. 2004).Control of inflammation
SERMs may also exert neuroprotective actions by the
control of local brain inflammation, which is mainly
regulated by microglia and astroglia. Tamoxifen and
raloxifene are able to decrease the inflammatory
response caused by lipopolysaccharide (LPS) in
mouse and rat microglia cells in vitro (Suuronen et al.
2005). In addition, these SERMs, at doses within the
range used in clinical practice, reduce microglia
activation in the central nervous system of male andJournal of Molecular Endocrinology (2011) 46, R1–R9female rats in vivo after the peripheral administration of
LPS (Tapia-Gonzalez et al. 2008). Figure 3 shows the
effect of tamoxifen and raloxifene on microglia
activation induced by the systemic administration of
LPS. Tamoxifen also reduces microglial inflammatory
response induced by irradiation (Liu et al. 2010). In
addition, raloxifene decreases the number of astrocytes
and microglia in the brain of aged animals (Lei et al.
2003). Furthermore, tamoxifen and raloxifene are able
to significantly reduce the number of reactive astrocytes
in the hippocampus of young, middle-aged, and older
female rats after a stab wound injury (Barreto et al.
2009). Some SERMs have also shown to be able to
reduce the inflammatory responses of astrocytes treated
with LPS by a mechanism involving ERs and the
inhibition of NF-kB-induced transcription of proin-
flammatory molecules (Cerciat et al. 2010).www.endocrinology-journals.org
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Figure 3 SERMs reduce microglia activation after the adminis-
tration of LPS in vivo. Representative images of the central white
matter of the cerebellum of male rats showing immunoreactivity
for MHC-II, a marker of activated microglia, after the i.p. injection
of (A) vehicles for SERMs (DMSO) and LPS (phosphate buffer);
(B) LPS; (C) 1 mg/kg tamoxifen and LPS; (D) 1 mg/kg raloxifene
and LPS. Insets show details of the morphology of MHC-II
immunoreactive cells at high magnification. LPS increases the
number of MHC-II immunoreactive microglial cells and induces
a reactive phenotype in microglia, with thicker and shorter cell
processes. SERMs revert the effect of LPS. Scale bar 100 mm.
In the insets, the scale bar represents 25 mm. Adapted, with
permission, from Tapia-Gonzalez S, Carrero P, Pernia O, Garcia-
Segura LM & Diz-Chaves Y 2008 Selective oestrogen receptor
(ER) modulators reducemicroglia reactivity in vivo after peripheral
inflammation: potential role of microglial ERs. Journal of
Endocrinology 198 219–230. q 2008 Society for Endocrinology.
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Figure 4 Summary of the molecular mechanisms involved in the
neuroprotective effects of SERMs. SERMs act in the nervous
system through classical ERs or by ER-independent mechanisms
and activate a variety of signaling molecules, including MAPK,
PI3K, Akt, CREB, and NF-kB. These molecules, in turn, trigger
different coordinated mechanisms to promote neuronal survival
and regulate mood and cognition.
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neuroprotection by SERMs
Figure 4 summarizes the mechanisms involved in the
neuroprotective actions of SERMs that have been
discussed in the previous sections. SERMs act on
neurons and glial cells and regulate the activity of
kinases, such as MAPK, PI3K, and Akt, which in turn
regulate the activity of factors that control transcription,
such as CREB and NF-kB. In addition, SERMs regulate
transcriptional activity of classical nuclear ERs. There-
fore, SERMs exert multiple actions on signaling
pathways that are involved in the modulation of
synaptic transmission, the regulation of apoptosis, the
control of oxidative stress, and the control of inflam-
mation. Furthermore, actions of SERMs in endocrine
glands may also contribute to their central actions by
the modulation of the levels of neuroactive molecules
such as b-endorphin and tetrahydroprogesterone or by
the control of peripheral inflammation. All these
actions of SERMs, exerted on neurons and glial cells,
probably contribute to their effects on neuronal
survival, mood, and cognition. However, the multiple
mechanisms activated by SERMs may also represent a
potential limitation for their use as neuroprotectants.www.endocrinology-journals.orgPerspectives for the future
Most of the studies showing neuroprotective actions of
SERMs have focused on tamoxifen and raloxifene.
These molecules are already in use in human clinic,
which may facilitate their application as brain thera-
peutic drugs. However, tamoxifen and raloxifene have
secondary effects that may limit their use and may block
in some cases neuroprotective actions of E2. New
SERMs, such as arzoxifene, bazedoxifene, lasofoxifene,
and ospemifene, among others, need to be explored in
experimental models of neurodegeneration. The few
available studies with these SERMs indicate that
bazedoxifene protects rat hippocampal neurons from
excitotoxic cell death in vivo (Ciriza et al. 2004) and that
ospemifene and bazedoxifene reduce the inflammatory
response of astrocytes exposed to LPS (Cerciat et al.
2010). More studies are also needed to define the
neuroprotective potential of natural SERMs (Azcoitia
et al. 2006, Schreihofer & Redmond 2009).
SERMs with better permeability of the blood–brain
barrier need to be developed, since the access of these
molecules to the central nervous system (CNS) mayJournal of Molecular Endocrinology (2011) 46, R1–R9
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as neuroprotectants. Furthermore, new SERMs with
preferential selectivity for activating estrogen
mechanisms in brain and specifically designed to act
as neuroprotectants are under development (Brinton
2004, Zhao et al. 2005). One of these molecules is
7a-[(4R,8R)-4,8,12-trimethyltridecyl]estra-1,3,5-trien-3,
17b-diol, a hybrid structure of E2 and vitamin E.
This molecule binds to both ERa and ERb and is
neuroprotective in rat primary hippocampal neurons
(Zhao et al. 2007). Other interesting molecules are
estrogen non-feminizing analogs with phenol groups
(Simpkins et al. 2005). Molecules such as 17a-E2, ent-E2,
2-adamantylestrone, and ent-17-desoxyestradiol have
been shown to be effective in the protection of neural
tissue under different neurodegenerative conditions
(Green et al. 2001, Liu et al. 2002, Yang et al. 2003,
Jung et al. 2006, Wang et al. 2006).
In general, there is still poor knowledge of the
precise molecular targets of SERMs in the nervous
system. Although some key molecules have been
identified, such as MAPK, PI3K/Akt, CREB, and
NF-kB, the molecular mechanisms involved in the
neuroprotective actions of SERMs should be investi-
gated with more detail in the different cellular
populations of the nervous system. Ideally, SERMs
with cellular specificity for neurons, astrocytes, oligo-
dendrocytes, and microglia may promote cell-specific
responses to decrease neuronal death, increase remye-
lination, enhance the production of neuroprotective
growth factors by astrocytes, and reduce the chronic
proinflammatory response of astrocytes and microglia.Declaration of interest
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